3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Neoplasms
7
Multiple Myeloma
7
Lymphoma
7
Carcinoma, Non-Small-Cell Lung
6
Lymphoma, T-Cell, Cutaneous
4
Mycosis Fungoides
3
Sezary Syndrome
2
Recurrence
2
Lymphoproliferative Disorders
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Vascular Diseases
1
Stage IIIB or IV Non-Small Cell Lung Cancer
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Myelodysplastic Syndromes
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Interventions
pembrolizumab
15
Pemetrexed
15
Cisplatin
12
Nivolumab
9
Carboplatin
8
Ipilimumab
7
tazemetostat
3
fludarabine
3
anetumab ravtansine
3
Cyclophosphamide
3
spartalizumab
2
budigalimab
2
belinostat
2
atezolizumab
2
amatuximab
2
Vinorelbine
2
Paclitaxel
2
Gemcitabine
2
Docetaxel
2
venetoclax
1
vandetanib
1
trametinib
1
tocilizumab
1
tislelizumab
1
sotorasib
1
ruxolitinib
1
rovalpituzumab tesirine
1
ribociclib
1
rebastinib
1
osimertinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mesothelioma
×
Vorinostat
×
Clear all
NCT00128102
2020-10-26
MK-0683-014
Merck Sharp & Dohme LLC
Phase 3
Completed
661 enrolled
18 charts